Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2012 Dec 19;104(24):1905-16.
doi: 10.1093/jnci/djs461. Epub 2012 Dec 6.

Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight Prospective Studies

Affiliations
Free PMC article
Meta-Analysis

Circulating Carotenoids and Risk of Breast Cancer: Pooled Analysis of Eight Prospective Studies

A Heather Eliassen et al. J Natl Cancer Inst. .
Free PMC article

Abstract

Background: Carotenoids, micronutrients in fruits and vegetables, may reduce breast cancer risk. Most, but not all, past studies of circulating carotenoids and breast cancer have found an inverse association with at least one carotenoid, although the specific carotenoid has varied across studies.

Methods: We conducted a pooled analysis of eight cohort studies comprising more than 80% of the world's published prospective data on plasma or serum carotenoids and breast cancer, including 3055 case subjects and 3956 matched control subjects. To account for laboratory differences and examine population differences across studies, we recalibrated participant carotenoid levels to a common standard by reassaying 20 plasma or serum samples from each cohort together at the same laboratory. Using conditional logistic regression, adjusting for several breast cancer risk factors, we calculated relative risks (RRs) and 95% confidence intervals (CIs) using quintiles defined among the control subjects from all studies. All P values are two-sided.

Results: Statistically significant inverse associations with breast cancer were observed for α-carotene (top vs bottom quintile RR = 0.87, 95% CI = 0.71 to 1.05, P(trend) = .04), β-carotene (RR = 0.83, 95% CI = 0.70 to 0.98, P(trend) = .02), lutein+zeaxanthin (RR = 0.84, 95% CI = 0.70 to 1.01, P(trend) = .05), lycopene (RR = 0.78, 95% CI = 0.62 to 0.99, P(trend) = .02), and total carotenoids (RR = 0.81, 95% CI = 0.68 to 0.96, P(trend) = .01). β-Cryptoxanthin was not statistically significantly associated with risk. Tests for heterogeneity across studies were not statistically significant. For several carotenoids, associations appeared stronger for estrogen receptor negative (ER(-)) than for ER(+) tumors (eg, β-carotene: ER(-): top vs bottom quintile RR = 0.52, 95% CI = 0.36 to 0.77, P(trend) = .001; ER(+): RR = 0.83, 95% CI = 0.66 to 1.04, P(trend) = .06; P(heterogeneity) = .01).

Conclusions: This comprehensive prospective analysis suggests women with higher circulating levels of α-carotene, β-carotene, lutein+zeaxanthin, lycopene, and total carotenoids may be at reduced risk of breast cancer.

Figures

Figure 1.
Figure 1.
Original (O) and recalibrated (R) medians of plasma or serum levels of carotenoids by study, among control subjects. *To convert μg/dL to μmol/L, multiply by the following factors: 0.01863 for α-carotene, β-carotene, and lycopene; 0.01810 for β-cryptoxanthin; 0.01758 for lutein+zeaxanthin. MEC = Multiethnic Cohort Study; NHS = Nurses’ Health Study; NYUWHS = New York University Women’s Health Study; SWHS = Shanghai Women’s Health Study; WHS = Women’s Health Study.
Figure 2.
Figure 2.
Relative risks (RRs) of breast cancer and 95% confidence intervals (CIs) according to quintile of plasma carotenoids (μg/dL), recalibrated data. Diamonds represent relative risks; lines represent 95% confidence intervals. To convert μg/dL to μmol/L, multiply by the following factors: 0.01863 for α-carotene, β-carotene, and lycopene; 0.01810 for β-cryptoxanthin; 0.01758 for lutein+zeaxanthin. ref = referent.
Figure 3.
Figure 3.
Relative risks (RRs) of breast cancer and 95% confidence intervals (CIs) according to quintile of plasma carotenoids, recalibrated data, by tumor estrogen receptor (ER) status. Diamonds represent relative risks; lines represent 95% confidence intervals. ER+ = estrogen receptor positive; ER = estrogen receptor negative; ref = referent.

Similar articles

See all similar articles

Cited by 51 articles

  • Development and validation of circulating CA125 prediction models in postmenopausal women.
    Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, Fichorova RN, Titus LJ, Tjønneland A, Hansen L, Kvaskoff M, Fournier A, Mancini FR, Boeing H, Trichopoulou A, Peppa E, Karakatsani A, Palli D, Grioni S, Mattiello A, Tumino R, Fiano V, Onland-Moret NC, Weiderpass E, Gram IT, Quirós JR, Lujan-Barroso L, Sánchez MJ, Colorado-Yohar S, Barricarte A, Amiano P, Idahl A, Lundin E, Sartor H, Khaw KT, Key TJ, Muller D, Riboli E, Gunter M, Dossus L, Trabert B, Wentzensen N, Kaaks R, Cramer DW, Tworoger SS, Terry KL. Sasamoto N, et al. J Ovarian Res. 2019 Nov 26;12(1):116. doi: 10.1186/s13048-019-0591-4. J Ovarian Res. 2019. PMID: 31771659 Free PMC article.
  • Urinary PGE-M Levels and Risk of Ovarian Cancer.
    Barnard ME, Beeghly-Fadiel A, Milne GL, Akam EY, Chan AT, Eliassen AH, Rosner BA, Shu XO, Terry KL, Xiang YB, Zheng W, Tworoger SS. Barnard ME, et al. Cancer Epidemiol Biomarkers Prev. 2019 Nov;28(11):1845-1852. doi: 10.1158/1055-9965.EPI-19-0597. Epub 2019 Aug 6. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 31387969 Free PMC article.
  • Chemoprevention of Breast Cancer With Vitamins and Micronutrients: A Concise Review.
    Mokbel K, Mokbel K. Mokbel K, et al. In Vivo. 2019 Jul-Aug;33(4):983-997. doi: 10.21873/invivo.11568. In Vivo. 2019. PMID: 31280187 Free PMC article. Review.
  • Dietary index scores and invasive breast cancer risk among women with a family history of breast cancer.
    Petimar J, Park YM, Smith-Warner SA, Fung TT, Sandler DP. Petimar J, et al. Am J Clin Nutr. 2019 May 1;109(5):1393-1401. doi: 10.1093/ajcn/nqy392. Am J Clin Nutr. 2019. PMID: 30968114 Free PMC article.
  • Predicting Circulating CA125 Levels among Healthy Premenopausal Women.
    Sasamoto N, Babic A, Rosner BA, Fortner RT, Vitonis AF, Yamamoto H, Fichorova RN, Tjønneland A, Hansen L, Overvad K, Kvaskoff M, Fournier A, Romana Mancini F, Boeing H, Trichopoulou A, Peppa E, Karakatsani A, Palli D, Pala V, Mattiello A, Tumino R, Grasso CC, Onland-Moret NC, Weiderpass E, Quirós JR, Lujan-Barroso L, Rodríguez-Barranco M, Colorado-Yohar S, Barricarte A, Dorronsoro M, Idahl A, Lundin E, Sartor H, Khaw KT, Key TJ, Muller D, Riboli E, Gunter MJ, Dossus L, Kaaks R, Cramer DW, Tworoger SS, Terry KL. Sasamoto N, et al. Cancer Epidemiol Biomarkers Prev. 2019 Jun;28(6):1076-1085. doi: 10.1158/1055-9965.EPI-18-1120. Epub 2019 Apr 4. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 30948451 Free PMC article.
See all "Cited by" articles

Publication types

MeSH terms

Feedback